COVID-19 drug development: Latest News, Top Stories & Analysis

RADNOR, PA — NRx Pharmaceuticals (Nasdaq: NRXP) announced that it recently filed a new Breakthrough Therapy Designation (BTD) request with the US Food and Drug Administration (FDA) focused on patients …

Health / Medical / National

FDA Authorizes Additional Oral Antiviral for Treatment of COVID-19 in Certain Adults

December 24, 2021December 24, 2021 - by MyChesCo

WASHINGTON, D.C. — The U.S. Food and Drug Administration has issued an emergency use authorization (EUA) for Merck’s molnupiravir for the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults with positive …

Health / Medical / National

FDA Authorizes First Oral Antiviral for Treatment of COVID-19

December 23, 2021December 23, 2021 - by MyChesCo

WASHINGTON, D.C. — The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for Pfizer’s Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) for the treatment of …

Health / Medical / National

FDA Expands Authorization of Two Monoclonal Antibodies for Treatment and Post-Exposure Prevention of COVID-19 to Younger Pediatric Patients, Including Newborns

December 6, 2021December 5, 2021 - by MyChesCo

WASHINGTON, D.C. — The U.S. Food and Drug Administration recently revised the emergency use authorization (EUA) of bamlanivimab and etesevimab (previously authorized for pediatric patients 12 years of age and older …

Regional

NRx Pharmaceuticals Identifies Significantly Higher Likelihood of Surviving and Recovering from Critical COVID-19 in ZYESAMI

December 1, 2021November 30, 2021 - by MyChesCo

RADNOR, PA — NRx Pharmaceuticals (Nasdaq: NRXP) announced this week that it has completed an analysis to identify clinical evidence that indicates a substantial improvement after treatment with ZYESAMI® (aviptadil) …

Health / Medical / National

Federal Government Secures 10 Million Courses of Pfizer’s COVID-19 Oral Antiviral Medicine

November 22, 2021November 19, 2021 - by MyChesCo

WASHINGTON, D.C. — The Biden Administration announced it recently secured 10 million treatment courses of Pfizer’s promising COVID-19 oral antiviral drug, contingent on emergency use authorization (EUA) or approval from …

Regional

USDA Declines Emergency Use Authorization for ZYESAMI® for Patients with COVID-19 with Respiratory Failure

November 12, 2021November 8, 2021 - by MyChesCo

RADNOR, PA — NRx Pharmaceuticals (NASDAQ: NRXP) announced that the US Food and Drug Administration (FDA) recently declined to issue an Emergency Use Authorization (EUA) for ZYESAMI® (aviptadil).

Regional

NRx Pharmaceuticals Announces Favorable, New Safety Report for ZYESAMI® (aviptadil) in NIH Sponsored ACTIV-3b Critical Care Study in Patients with COVID-19

November 9, 2021November 8, 2021 - by MyChesCo

RADNOR, PA — NRx Pharmaceuticals (NASDAQ: NRXP) provided a recent safety update on ZYESAMI® (aviptadil), which is being tested in the ACTIV-3b Critical Care Phase 3 study sponsored by the …

Products and Services / Research

Immunome Announces Submission for Publication of Pre-clinical Research for SARS-CoV-2 Treatment and Prophylaxis

October 25, 2021October 25, 2021 - by MyChesCo

EXTON, PA — Immunome, Inc. (Nasdaq: IMNM) announced that it recently submitted to bioRxiv a preprint of a manuscript regarding preclinical research of the company’s SARS-CoV-2 antibody cocktail, IMM-BCP-01. The …

National

FDA to Hold Advisory Committee Meeting to Discuss Merck and Ridgeback’s EUA Application for COVID-19 Oral Treatment

October 18, 2021October 18, 2021 - by MyChesCo

WASHINGTON, D.C. — The U.S. Food and Drug Administration announced an upcoming meeting of its Antimicrobial Drugs Advisory Committee (AMDAC) to discuss Merck and Ridgeback’s request for an emergency use …